New Shot-Based immunotherapy combo tested for lung cancer

NCT ID NCT06946797

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy. It includes 76 adults with advanced or recurrent non-small cell lung cancer who have not had prior treatment for their advanced disease. The main goal is to measure drug levels in the blood and check safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Local Institution - 0003

Suresnes, Hauts-de-Seine, 92151, France
Local Institution - 0009

Sandton, GP, 2196, South Africa
Local Institution - 0010

Paris, Île-de-France Region, 75014, France
Local Institution - 0011

Thessaloniki, Kentrikí Makedonía, 540 07, Greece
Local Institution - 0012

Athens, Attikí, 115 27, Greece
Local Institution - 0013

Chaïdári, Attikí, 12462, Greece
Local Institution - 0014

Larissa, Thessalía, 41110, Greece
Local Institution - 0015

Meldola, Emilia-Romagna, 47014, Italy
Local Institution - 0017

Novara, 28100, Italy
Local Institution - 0019

Florence, Tuscany, 50134, Italy
Local Institution - 0020

Bergamo, Lombardy, 24127, Italy
Local Institution - 0031

Soweto, Gauteng, 2013, South Africa
Local Institution - 0032

Anchorage, Alaska, 99508, United States
Local Institution - 0033

Cleveland, Ohio, 44109, United States
Local Institution - 0034

São Paulo, 01246-000, Brazil
Local Institution - 0037

Barretos, São Paulo, 14784400, Brazil
Local Institution - 0038

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Local Institution - 0041

Brasília, Federal District, 70200-730, Brazil
Local Institution - 0043

Belo Horizonte, Minas Gerais, 30380-490, Brazil
Local Institution - 0047

Cleveland, Ohio, 44106, United States
Local Institution - 0051

Allentown, Pennsylvania, 18103, United States
Local Institution - 0052

Boise, Idaho, 83706, United States
Local Institution - 0057

Udine, Friuli Venezia Giulia, 33100, Italy
Local Institution - 0062

Los Angeles, California, 90033, United States
Local Institution - 0063

Boise, Idaho, 83702, United States
Local Institution - 0064

Post Falls, Idaho, 83854, United States
Local Institution - 0065

Dijon, Côte-d'Or, 21079, France
Local Institution - 0067

Santiago, Santiago Metropolitan, 8420383, Chile
Local Institution - 0073

Bucharest, Bucharest, 022328, Romania
Local Institution - 0074

Cluj-Napoca, 400015, Romania
Local Institution - 0075

Bucharest, 020335, Romania
Local Institution - 0076

Florești, Cluj, 407280, Romania
Local Institution - 0077

Craiova, Dolj, 200542, Romania
Local Institution - 0078

Iași, 700483, Romania
Local Institution - 0079

Lodz, Łódź Voivodeship, 93-338, Poland
Local Institution - 0080

Prabuty, Pomeranian Voivodeship, 82-550, Poland
Local Institution - 0081

Warsaw, Masovian Voivodeship, 03-411, Poland
Local Institution - 0084

Rondebosch, Western Cape, 7700, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.